News

Fierce Pharma14h
ASCO: Roche, Jazz's Zepzelca small cell lung cancer win leaves room for improvement
Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...
Fierce Pharma20h
AstraZeneca, Merck duke it out at the top of oncologists’ pharma perception ranking
ZoomRx polled 50 experienced oncologists and hemato-oncologists about 20 cancer drugmakers, asking the doctors to rank the ...
The Pharma Letter1d
Big build-up for AstraZeneca’s ASCO offering
Anglo-Swedish pharma major AstraZeneca reports that it will have a historic presence at this year’s American Society of ...
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a ...
AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the American Society of Clinical Oncology (ASCO) ...
MyChesCo on MSN6d
AstraZeneca’s IMFINZI® Demonstrates Promising Results in POTOMAC Phase III Trial for High-Risk NMIBC
AstraZeneca has announced positive high-level results from its Phase III POTOMAC trial assessing the efficacy of IMFINZI® ...
Precision Medicine Online6d
Real-World Data Show 72 Percent of Bladder Cancer Patients Got Genomic Testing in Community Network
The analysis by Ontada tracked testing rates withing the US Oncology Network for PD-L1, FGFR2/3, and HER2 biomarkers over 10 years.